ASH 2023 FEATURED NHLBI PRESENTATIONS

Saturday, December 9

Oral Abstract 33
Hematopoietic Stem Cells from Mice and Individuals with Sickle Cell Disease Display Premature Senescence and Loss of Function that is Targetable By Senolytic Therapy
Aditya Barve, Ph.D.
10 a.m. PT
San Diego Convention Center, Room 24

Education Program
When to Consider Inherited Marrow Failure Syndromes in Adults
Emma Groarke, M.D.
2 – 3:15 p.m. PT
San Diego Convention Center, Room 24

Oral Abstract 247
Successful Implementation Trial to Improve Stroke Risk (TCD) Screening in Children with Sickle Cell Anemia: A Roadmap to Care Enhancement
Julie Kanter, M.D.
2 p.m. PT
Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

Oral Abstract 201
Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-Up of a Phase 2 Study
Adrian Wiestner, M.D.
2:30 p.m. PT
Manchester Grand Hyatt San Diego, Grand Hall D

Oral Abstract 150
Enhanced Expression of Heme Oxygenase-1 (HO-1) Among Children with Sickle Cell Disease: Results of the Sickle Cell Disease Genomics of Africa (SickleGenAfrica) Study
Anna Sowa, M.D.
3:15 p.m. PT
San Diego Convention Center, Room 31

Oral Abstract 273
Long-Term Safety and Efficacy of Mitapivat, an Oral Pyruvate Kinase Activator, in Adults with Sickle Cell Disease: Extension of a Phase 1 Dose Escalation Study
4:30 p.m. PT
San Diego Convention Center, Room 28 A-D
Oral Abstract 345
**Microbiota-Specific T Cells Contribute to Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation**
Albert Yeh, M.D.
4:30 p.m. PT
San Diego Convention Center, Room 7

Oral Abstract 371
**Assessing Psychosocial Readiness for Gene Therapy in Sickle Cell Disease: A Consensus Statement**
Steven J. Hardy, Ph.D.
5 p.m. PT
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 2-4

*Sunday, December 10*

Oral Abstract 424
**Measurable Residual IDH2 Before Allogeneic Transplant for Acute Myeloid Leukemia**
Gege Gui, Sc.M.
10:15 a.m. PT
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Oral Abstract 486
**CD117 Antibody-Drug Conjugate Conditioning Allows Efficient Engraftment of Gene-Modified CD34+ Cells with Fertility Preservation in a Rhesus Gene Therapy Model**
Naoya Uchida, M.D., Ph.D.
10:45 a.m. PT
San Diego Convention Center, Ballroom 2CD

**ASH Mentor Award**
Helen Heslop, M.D., D.Sc.
1:30 – 2:30 p.m. PT
San Diego Convention Center, Hall A

**ASH Award for Leadership in Promoting Diversity**
Alexis A. Thompson, M.D., M.P.H.
1:30 – 2:30 p.m. PT
San Diego Convention Center, Hall A

**Plenary Scientific Session 3**
**Synthetic Introns Identify the Novel RNA Splicing Factor GPATCH8 As Required for Mis-Splicing Induced By SF3B1 Mutations**
Salima Benbarche, Ph.D.
2 – 4 p.m. PT
San Diego Convention Center, Hall A
Plenary Scientific Session 5
Metabolic Programming of Hematopoietic Stem Cell Function by Prenatal Folate
Brian Krum, M.Sc.
2 – 4 p.m. PT
San Diego Convention Center, Hall A

Plenary Scientific Session 6
Hydroxyurea Dose Optimization Is Safe and Improves Outcomes for Children with Sickle Cell Anemia Living in Sub-Saharan Africa: The Reach Experience
Banu Aygun, M.D.
2 – 4 p.m. PT
San Diego Convention Center, Hall A

Monday, December 11

Oral Abstract 703
Clinical Manifestations Are Evolving and Progressive in Patients with Vexas Syndrome
Bhavisha Patel, M.D.
10:30 a.m. PT
San Diego Convention Center, Room 6DE

Oral Abstract 1051
Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up
Julie Kanter, M.D.
4:30 p.m. PT
San Diego Convention Center, Hall A

Education Program
Gene Therapy for Sickle Cell Disease
John F. Tisdale, M.D.
4:30 – 5:45 p.m. PT
San Diego Convention Center, Room 29

Oral Abstract 929
SCD Dyslipidemia Normalizes Long-Term Following Nonmyeloablative Hematopoietic Cell Transplantation
Jackie Queen, M.D., M.P.H.
5:30 p.m. PT
San Diego Convention Center, Room 31
Oral Abstract 941
Clonal Derivation and Dynamics in Rhesus Macaques Following Hematopoietic Stem Cell Transplantation and the Impact of Clonal Hematopoiesis
Yifan Zhou, M.S.
5:30 p.m. PT
San Diego Convention Center, Room 24

Oral Abstract 1062
Identifying Geriatric Syndromes in Adults with Sickle Cell Disease Using the Sickle Cell Disease Functional Assessment (SCD-FA): The Sickle Cell Disease Functional Assessment Validation and Refinement (SILVR) Study
Charity I. Oyedeji, M.D.
5:45 p.m. PT
Marriott Marquis San Diego Marina, Marriott Grand Ballroom 8-9

Tuesday, December 12

Henry M. Stratton Medal
James B. Bussel, M.D.
8:45 – 9 a.m. PT
San Diego Convention Center, Hall A

Late-Breaking Abstracts 3
PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life
Keith McCrae, M.D.
9 – 10:30 a.m. PT
San Diego Convention Center, Hall A

Late-Breaking Abstracts 4
Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell
Adetola Kassim, M.B.B.S., M.S.
9:45 – 10 a.m. PT
San Diego Convention Center, Hall A

Presidential Symposium
The Complement System and Targeted Therapies – Intracellular Complement and Adoptive Immunity
Claudia Kemper, Ph.D.
11 a.m. – 12:30 p.m. PT
San Diego Convention Center, Hall A